India and Brazil sign MoU to align pharma and medical product regulation, boosting supply chains and access to care.
India and Brazil on Friday exchanged a Memorandum of Understanding (MoU) to strengthen bilateral cooperation in the regulation of pharmaceutical and medical products, marking a significant step toward deeper health-sector collaboration between the two Global South partners.
The MoU was exchanged between India’s Central Drugs Standard Control Organisation and Brazil’s Brazilian Health Regulatory Agency (ANVISA) at Hyderabad House. The agreement was exchanged by Leandro Safatle, Director-President of ANVISA, and Dinesh Bhatia, India’s Ambassador to Brazil, in the presence of Prime Minister Narendra Modi and President Luiz Inácio Lula da Silva.
The MoU establishes a structured framework for cooperation and information exchange covering pharmaceutical ingredients, drugs, biological products and medical devices. It seeks to promote convergence in regulatory practices, enhance mutual understanding of regulatory systems and enable more effective and coordinated oversight of medical products.
Officials said the agreement reflects the shared commitment of both countries to ensuring the availability of safe, effective and quality-assured medicines and medical products for their populations. It is also expected to strengthen supply chains, encourage regulatory best practices and support access to affordable healthcare solutions.
Building on broader India–Brazil cooperation in the health sector, the MoU complements existing institutional mechanisms for bilateral engagement and underscores the expanding collaboration in pharmaceuticals and medical technologies. The partnership is particularly significant in the context of shared priorities among leading Global South economies.
Under the agreement, both sides will work closely on information sharing, regulatory capacity building and cooperation in pharmaceutical and medical product regulation, in line with their respective national laws and frameworks.
The exchange of the MoU is expected to further reinforce India–Brazil relations and open new avenues for collaboration in health and pharmaceuticals, contributing to stronger regulatory systems and improved public health outcomes in both countries.
Source: PIB
